Introduction
============

Of all pancreatic tumors, pancreatic neuroendocrine tumors (pNETs) only account for 1% to 5% and are rare and highly heterogeneous neuroendocrine tumors[@B1]-[@B3]. With the attention and technology improvement, the incidence has increased in 2 to 3 fold over the past decades[@B4]-[@B6]. Due to its peculiarity of occult malignancy and indolent characteristics, pNETs patients have a limited survival outcome with a 5-year survival rate of 80%-90% after resected surgery[@B3], [@B7], [@B8]. Thus, a powerful and accurate staging system applied for survival prediction and risk stratification is urgently required[@B7], [@B9], [@B10].

A consensus published for TNM staging classification of pNETs by the European Neuroendocrine Tumor Society (ENETS) in 2006 has been validated and applied in amounts of studies[@B11]-[@B15]. Apart from that, various studies have also demonstrated the applicability of the AJCC 7th staging system for pNETs [@B16]-[@B19]. Considering their drawbacks, Guopei Luo et al[@B7] creatively put forward the modified ENETS (mENETS) staging classification which maintained the ENETS T, N and M definitions and also adopted the AJCC 7th staging definitions. The mENETS staging system overcame the disorder both between the stage I and IIA diseases and between stage IIIA and IIIB diseases using the ENETS staging system, and the small number of stage III diseases using the AJCC 7th staging system. However, the mENETS stage system was not applicable for all situations and further improvement was called for to address the problems that clinical practitioners may encounter. As the AJCC 8th staging system for pancreatic ductal adenocarcinoma (PDAC) allowed for finer risk stratification of patients with resected tumors according to extent of nodal involvement[@B20], the classification changes to the AJCC staging system for PDAC may also benefit for the improvement of ENETS staging system.

This study was mainly aimed to obtain a more accurate staging system in a framework of analysis of the application based on ENETS and AJCC 8th N classifications for PDAC. The reformed ENETS (rENETS) staging classification would maintain the ENETS T, M definitions and AJCC 8th N definitions of PDAC and adopt the AJCC 8th staging definitions of PDAC. Combined with the created rENETS staging system, we managed to formulate a novel nomogram to improve the discrimination ability of survival prediction.

Materials and methods
=====================

Patient population and data source
----------------------------------

The data used in our study were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database registry of National Cancer Institute. The pNET patients were enrolled based on column of Site and Morphology (Primary Site - labeled) for tumor of pancreas which was labeled as C25.0 to C25.9. Then according to the International Classification of Diseases for Oncology (3rd edition) for tumor of histology/behavior, pancreatic endocrine tumor, malignant (8150/3), insulinoma, malignant (8151/3), glucagonoma, malignant (8152/3), gastrinoma, malignant (8153/3), mixed pancreatic endocrine and exocrine tumor, malignant (8154/3), vipoma, malignant (8155/3), carcinoid tumor (8240/2), Enterochromaffin cell carcinoid (8241/3), enterochromaffin-like cell tumor, malignant (8242/3), goblet cell carcinoid (8243/3), mixed adenoneuroendocrine carcinoma (8244/3), adenocarcinoid tumor (8245/3), neuroendocrine carcinoma (8246), and atypical carcinoid tumor (8249/3) were all included. Another selection criterion was the diagnosis of year from 2004 to 2012.

The following data were obtained for each patients: sex, race, age, primary site, primary lesion amounts, tumor type, grade, surgery decision, TNM stage and survival information. The TNM stage of AJCC 7th edition, ENETS, mENETS and rENETS were evaluated according to the following codes: collaborative stage (CS) tumor size 2004, CS extension 2004, CS lymph nodes 2004, CS metastases at DX 2004, derived AJCC stage group (6th edition; 2004+), derived AJCC stage group (7th edition; 2010+). In addition, patients lacking of survival information or certain TNM stage, or with unknown characteristics were excluded in this study.

Statistical analysis
--------------------

Statistical analyses were conducted using R project version 3.3.3 (<http://www.r-project.org/>) and SPSS 21.0 statistical package (SPSS Inc., Chicago, IL, USA) for Windows. The overall survival (OS) depicted by Graphpad Prism6 program was analyzed using Kaplan-Meier curves and compared by the log-rank test. The Cox proportional hazards regression model was used for univariate and multivariate analyses and hazard ratios (HR) to identify independent prognostic factors, and *P* value less than 0.05 was defined statistically significant.

One novel prognostic nomogram for OS based on the results of multivariate analysis was established by the rms package in R project. The predictive performance of the nomogram was further measured by concordance index (C-index), calibration curve and decision curve analysis (DCA)[@B21]. Bootstraps with 1,200 resample were used for these activities. The predictive comparisons were evaluated by C-index between the established nomogram and other independent index.

Results
=======

Clinicopathological characteristics
-----------------------------------

According to the whole criteria above, 2,209 patients with histopathological confirmed pNETs from the SEER database were finally enrolled in this study and the detailed clinicopathological characteristics were tabulated in **Table [1](#T1){ref-type="table"}**. In this whole population, there were 1182 males and 1027 females, with a median age of 60 (ranging from 18 to 91). Approximately 80% of patients were Caucasian. The number of patients with a tumor located at the head of pancreas was similar to that at the tail of pancreas. pNETs with only one primary lesion constituted the majority (77.4%) and 83.2% of patients were diagnosed as nonfunctional pNETs. Approximately 85% of patients possessed high and intermediate pathological differentiation. In the decision of therapy, 1557 patients received surgery and 599 patients were not recommended for surgery, while 53 patients were recommended for surgery but somehow not performed. The median survival time was 98.0 months (ranges, 0-131 months). Furthermore, the OS rates at 5, 8 and 10 years were 62.5%, 50.3% and 43.1% respectively. According to the AJCC 7th edition, ENETS stage, mENETS stage and rENETS stage, the number of patients with separate stage was recorded respectively.

Independent prognostic factors
------------------------------

The univariate analysis results showed that age, sex, tumor type, grade, surgery and all TNM stages could be considered as influence factors in pNETS survival (**Table [1](#T1){ref-type="table"}**). In the further multivariate analysis for OS, age, sex, grade, surgery and all TNM stages remained as independent risk indicators for tumor OS (**Table [2](#T2){ref-type="table"}**).

AJCC 7th staging system and survival
------------------------------------

Only 3.6% (79 of 2,209) of patients could be classified into stage III tumors on the basis of the AJCC 7th staging classification (**Table [1](#T1){ref-type="table"}**), and stage IIA and stage IIB tumors showed the adverse prognostic trends (**Fig. [1](#F1){ref-type="fig"}a**). In addition, the discrimination between stage III and IV diseases was smaller in the first half of survival curve, while it showed similarity between stage II and III diseases in the second half (**Fig. [1](#F1){ref-type="fig"}b**). The HR of stage III by multivariable analyses was 2.236, which was comparable to stage IV with HR as 3.194 when compared with stage I tumor (**Table [2](#T2){ref-type="table"}**).

ENETS staging system and survival
---------------------------------

It was awful that all survival curves except stage IV disease were complex and disordered. The overlaps were noticed between the ENETS classification of stage I, IIA and IIB disease, and between stage IIIA and IIIB disease which was even upside down (**Fig. [1](#F1){ref-type="fig"}c**). Furthermore, it was obvious that stage I and II disease couldn\'t be distinguished from each other (**Fig. [1](#F1){ref-type="fig"}d**) and no statistical significance was analyzed with HR by a multivariable analysis between stage I and II disease (HR, 1.338; P =0.154; **Table [2](#T2){ref-type="table"}**).

Modified ENETS staging system and survival
------------------------------------------

Considering the above shortcomings of the AJCC 7th and ENET staging systems, mENETS staging classification was proposed previously by maintaining the ENETS T, N, and M definitions and adopting the AJCC 7th staging definitions. Through these changes, the proportion of patients of stage III disease using the mENETS staging classification was higher than that of the AJCC 7th staging classification (23.0% v 3.6%; **Table [1](#T1){ref-type="table"}**). According to the mENETS classification, survival curves of all stages were well separated, which was further confirmed by the reasonable HRs with statistical significance (**Fig. [1](#F1){ref-type="fig"}e and [1](#F1){ref-type="fig"}f**; **Table [2](#T2){ref-type="table"}**).

Reformed ENETS staging system and survival
------------------------------------------

Compared to 7th staging system, the rENETS staging system changed the T and N classification. The N classification was defined more precisely. The distinction between stage IIB and III disease using the rENETS staging classification was larger than that of the mENETS staging classification, so did stage II and stage III disease (**Fig. [1](#F1){ref-type="fig"}g and [1](#F1){ref-type="fig"}h**). According to the rENETS staging system, survival curves were also separated as better as that in the mENETS staging system between stages and a tiny increase in HRs was observed with statistical significance (**Table [2](#T2){ref-type="table"}**).

Prognostic nomogram for OS
--------------------------

One prognostic nomogram integrated the prognostic TNM staging system and all significant independent prognostic factors for OS was developed by multivariate Cox regression models. The C-index for OS prediction with the formulated nomogram containing rENETS staging system was 0.821 (95% CI, 0.820 to 0.822), which was the same as the nomogram containing the mENETS staging system and higher than the C-index by other independent factors (**Table [3](#T3){ref-type="table"}**). The higher C-index reflected the better predictive accuracy for OS achieved. Through the analysis of survival curves, HRs and C-index, the rENETS staging system showed the superior performance in the prediction for OS of pNETs, and nomogram containing rENETS staging system was formulated to predict the survival with larger advantage (**Fig. [2](#F2){ref-type="fig"}**).

Validation of predictive accuracy of the nomogram with calibrations and decision curve analysis
-----------------------------------------------------------------------------------------------

The calibration plot for the probability of OS at 5,8,10 years showed optimal consistency between the observed OS and nomogram-predicted OS (**Fig. [3](#F3){ref-type="fig"}a-c**). The C-index of the formulated nomogram for OS prediction was 0.821 higher than that of the rENETS staging system or grade alone (0.710 and 0.689, respectively; **Table [3](#T3){ref-type="table"}**).

On DCA, an original evaluation method to highlight predictive models with the clinical net benefit[@B22], [@B23], the formulated nomogram yielded superior net benefit along with a wider scope of threshold probability in contrast to the rENETS staging system alone (**Fig. [3](#F3){ref-type="fig"}d and [3](#F3){ref-type="fig"}f**). This indicated higher predictive power for predicting 5-, 8-, 10-year OS. Meanwhile, higher threshold probability levels meant superior evaluation of decision outcomes.

Discussion
==========

In this study, over 2,000 patients from SEER database were systematically analyzed. Consistent to a previous study[@B7], the lower proportion of stage III disease (3.6%) with the AJCC 7th staging system, or a similar prognosis between patients with stage I disease and stage II disease (P = 0.154) using the ENETS staging system suggested that both of them were far from a rational classification for pNETs. In addition, the HR of death for patients with stage IIIB disease was also found lower than that for patients with stage IIIA disease in the ENETS staging system (HR for stage IIIA, 3.325; HR for stage IIIB, 3.053, with stage I as the reference). In the comparison between the mENETS and rENETS staging system, we could directly discover that the changes of HR for patients in stage II and III disease, or stage III and IV disease with the mENETS staging system was slightly lower than that with the rENETS staging system, so did the discrimination ability in the survival curves. In the univariate and multivariate analysis, rENETS staging system, grade, surgery, age and sex were finally discovered as the independent prognostic factors. One novel nomogram was established to predict the 5-, 8- and 10- OS rates of pNET patients based on all the independent prognostic factors. The C-index of the formulated nomogram was 0.821 which was larger than other risk factors alone. Furthermore, calibrations and DCA validated our nomogram. The large sample size and wide distribution of patients in this cohort could guarantee its representativeness for pNETs.

Controversy still remains on whether the patients\' survival is related to lymph node metastasis[@B24]-[@B27]. Although Krampit et al.[@B25] had considered the links between the number of lymph nodes and survival, he just applied two lymph nodes as the cut-off value, which was limited and blurry. One major character of pNETs was its tendency of metastasis and recurrence, and many studies confirmed that distant metastasis could promote nodal metastasis and unfavorably influenced the survival of pNET patients[@B28]-[@B30]. In our study, stage IV disease accounted for more than 30%, showing the necessity of ideal nodal substage for pNTEs. The N classification in AJCC 8th staging system performed better in risk stratification of pancreatic ademocarcinoma[@B20], so was the incorporation of AJCC 8th N-stage revision into the ENETS staging system performed superior prediction in survival of pNET patients. In a previous study, Luo et al.[@B31] had illustrated the significance of N classification in pNETs patients, however, one single study is unlikely to provide enough information to illustrate the efficacy of the chosen N classification, which even possibly could lead to selection bias. The AJCC 8th N classification was widely used in pancreatic tumor and confirmed its validity. A highlighted improvement was obtained with our revised rENETS staging system and more clinical decisions may benefit from it.

Except the TNM staging system, there are a plethora of other indicators for the prognosis of pNET patients. Through our analysis, the grade, surgery, age and sex were independent predictors for OS, consistent to the previous reports[@B27], [@B32]. Grade reflected tumor biological behavior and was closely connected to its prognosis[@B33]. Lianyuan et al.[@B34] had confirmed that surgical resection of primary lesion was associated with OS (P=0.025) benefit as well as other studies[@B35]. Non-resection was a potential risk factor associated with poor survival. From the constructed nomogram, we found the pNET patients who had tumor resected obtained better survival. Intriguingly, the patients who was recommended with surgery but not performed finally had higher risk than those was not recommended, which suggested reduction in tumor load was significant to survival of pNETs. The age, surgery, grade and TNM staging system were all attributed in high risk factors with wider range of points. However, sex as an independent predictor had relatively lower risk.

Validation of the formulated nomogram was significant to avoid overfitting of the model and reveal the representativeness[@B36]. In this study, calibration curves showed a superior consistency between nomogram-predicted and actually observed probability, and DCA revealed superior clinical benefit with a wider range of threshold probability, which could guarantee the reliability of the formulated nomogram. Its limitations were retrospective in nature and lack of blood serum indices and specific proteins, so prospective multicenter clinical trials should be carried out to make further efforts in validating our results and comparing to other models.

In conclusion, the novel rENETS staging system showed excellent performance in the risk stratification and the formulated nomogram could obtain a wider range in prognostic prediction for pNETs.
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:   Surveillance, Epidemiology, and End Results

CS
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:   hazard ratios
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:   overall survival

C-index

:   concordance index

DCA

:   decision curve analysis.

Informed consent
================

The primary and processed data were downloaded from SEER database. All SEER data were available with no restriction in presentations or publications according to its guidelines.

![**Kaplan-Meier curves of different staging classifications for patients from the SEER database.** (a and b) AJCC 7th staging system; (c and d) ENETS; (e and f) mENETS; and (g and h) rENETS staging system. Overlap existed between (a) the AJCC 7th classification stages III and IV disease and (c) the ENETS classification stages I and II disease. Survival curves were well separated by stage using (e, g) the modified ENETS classification and reformed ENETS classification. SEER: Surveillance, Epidemiology, and End Results; AJCC: American Joint Committee on Cancer; ENETS: European Neuroendocrine Tumor Society; mENETS: modified European Neuroendocrine Tumor Society; rENETS: reformed European Neuroendocrine Tumor Society.](jcav09p1698g001){#F1}

![**Prognostic nomogram analysis for pNETS.** The nomogram predicts OS in patients with pNETs (to use the nomogram, an individual patient\'s value is located on each variable axis, and a line is drawn upwards to determine the number of points received for each variable value. The sum of these number is located on the total points axis, and a line is drawn downwards to the survival axes to determine the likelihood of 5-, 8-, 10-year OS). pNETS, pancreatic neuroendocrine tumors; OS, overall survival; rENETS, reformed European Neuroendocrine Tumor Society.](jcav09p1698g002){#F2}

![**Prognostic calibration curves and decision curve analysis for pNETS.** The calibration curves predict OS at 5 years (a), 8 years (b) and 10 years (c) in the patient with pNETs. Decision curve analyses depict the clinical net benefit in pairwise comparisons across the different models. Nomogram is compared with the rENETS staging system in terms of 5-(d), 8-(e), 10-year(f) OS in the patient with pNETs. Dashed lines indicate the net benefit of the predictive models across a range of threshold probabilities (black: nomogram; red: rENETS staging system+G; green: rENETS staging system. The horizontal solid black line represents the assumptions that no patient will experience the event, and the solid grey line represents the assumption that all patients will experience the event. On decision curve analysis, the nomograms showed superior net benefit compared with rENETS+G and rENETS staging system across a wider range of threshold probabilities. pNETS, pancreatic neuroendocrine tumors; OS, overall survival; rENETS, reformed European Neuroendocrine Tumor Society.](jcav09p1698g003){#F3}

###### 

Clinicopathologic characteristics: univariate analysis.

  Variables                       Patients N=2209   OS               
  ------------------------------- ----------------- ------ --------- ---------------------
  Age, years                                               \<0.001   1.901 (1.721-2.100)
  \<40                            180               8.1              
  40-59                           886               40.1             
  60-79                           994               45.0             
  ≥80                             149               6.7              
  Sex                                                      \<0.001   1.343 (1.168-1.546)
  Female                          1027              46.5             
  Male                            1182              53.5             
  Race                                                     0.394     1.051 (0.937-1.179)
  Asian                           183               8.3              
  Black                           247               11.2             
  White                           1762              79.8             
  Others                          17                0.8              
  Primary site                                             0.201     0.961 (0.905-1.021)
  Head                            668               30.2             
  Body                            289               13.1             
  Tail                            727               32.9             
  Others                          525               23.8             
  Primary lesion amounts                                   0.281     1.069 (0.947-1.206)
  1                               1709              77.4             
  2                               388               17.6             
  ≥3                              112               5.1              
  Tumor type                                               \<0.001   1.501 (1.211-1.859)
  Functional                      371               16.8             
  Nonfunctional                   1838              83.2             
  Grade                                                    \<0.001   2.473 (2.278-2.685)
  High                            1449              65.6             
  Intermediate                    399               18.1             
  Low                             361               16.3             
  Surgery                                                  \<0.001   2.360 (2.198-2.533)
  Performed                       1557              70.5             
  Recommended but not performed   53                2.4              
  Not recommended                 599               27.1             
  AJCC 7th stage                                           \<0.001   1.532 (1.465-1.601)
  IA                              378               17.1             
  IB                              409               18.5             
  IIA                             195               8.8              
  IIB                             391               17.7             
  III                             79                3.6              
  IV                              757               34.3             
  ENETS stage                                              \<0.001   1.586 (1.505-1.673)
  I                               378               17.1             
  IIA                             250               11.3             
  IIB                             159               7.2              
  IIIA                            239               10.8             
  IIIB                            426               19.3             
  IV                              757               34.3             
  mENETS stage                                             \<0.001   1.610 (1.524-1.701)
  IA                              378               17.1             
  IB                              250               11.3             
  IIA                             159               7.2              
  IIB                             158               7.2              
  III                             507               23.0             
  IV                              757               34.3             
  rENETS stage                                             \<0.001   1.612 (1.525-1.703)
  IA                              378               17.1             
  IB                              250               11.3             
  IIA                             159               7.2              
  IIB                             141               6.4              
  III                             524               23.7             
  IV                              757               34.3             

OS, overall survival; AJCC, American Joint Committee on Cancer; ENETS, European Neuroendocrine Tumor Society; HR, hazard ratio; mENETS, modified European Neuroendocrine Tumor Society; rENETS, reformed European Neuroendocrine Tumor Society.

###### 

Multivariate analysis of prognostic factors.

  Variables                       AJCC 7th stage   ENETS stage           mENETS stage   rENETS stage                                                    
  ------------------------------- ---------------- --------------------- -------------- --------------------- --------- --------------------- --------- ---------------------
  Age, year                                                                                                                                             
  \<40                            1                                      1                                    1                               1         
  40-59                           0.036            1.469 (1.025-2.105)   0.033          1.478 (1.032-2.118)   0.037     1.466 (1.023-2.102)   0.038     1.465 (1.022-2.101)
  60-79                           \<0.001          2.525 (1.776-3.592)   \<0.001        2.528 (1.777-3.595)   \<0.001   2.496 (1.755-3.551)   \<0.001   2.494 (1.753-3.548)
  ≥80                             \<0.001          4.326 (2.909-6.432)   \<0.001        4.319 (2.904-6.422)   \<0.001   4.257 (2.863-6.330)   \<0.001   4.257 (2.863-6.330)
  Sex                                                                                                                                                   
  Female                          1                                      1                                    1                               1         
  Male                            0.002            1.251 (1.086-1.441)   0.002          1.251 (1.087-1.441)   0.002     1.256 (1.091-1.447)   0.002     1.255 (1.090-1.445)
  Tumor type                                                                                                                                            
  Functional                      1                                      1                                    1                               1         
  Nonfunctional                   0.402            1.097 (0.883-1.363)   0.400          1.098 (0.884-1.363)   0.364     1.106 (0.890-1.373)   0.370     1.104 (0.889-1.372)
  Grade                                                                                                                                                 
  High                            1                                      1                                    1                               1         
  Intermediate                    0.019            1.251 (1.038-1.509)   0.021          1.246 (1.033-1.502)   0.021     1.247 (1.034-1.503)   0.020     1.249 (1.036-1.506)
  Low                             \<0.001          3.567 (3.021-4.213)   \<0.001        3.562 (3.017-4.206)   \<0.001   3.585 (3.036-4.234)   \<0.001   3.584 (3.035-4.232)
  Surgery                                                                                                                                               
  Performed                       1                                      1                                    1                               1         
  Recommended but not performed   \<0.001          3.289 (2.263-4.779)   \<0.001        3.265 (2.246-4.745)   \<0.001   3.144 (2.164-4.567)   \<0.001   3.151 (2.169-4.578)
  Not recommended                 \<0.001          2.765 (2.325-3.289)   \<0.001        2.783 (2.348-3.300)   \<0.001   2.752 (2.322-3.260)   \<0.001   2.749 (2.320-3.257)
  Stage                                                                                                                                                 
  I                               1                                      1                                    1                               1         
  II                              \<0.001          1.988 (1.556-2.540)   0.154          1.338 (0.897-1.995)   0.001     1.735 (1.251-2.406)   0.002     1.703 (1.220-2.377)
  III                             \<0.001          2.236 (1.527-3.274)   \<0.001        2.429 (1.706-3.459)   \<0.001   2.270 (1.718-3.998)   \<0.001   2.271 (1.722-2.996)
  IV                              \<0.001          3.194 (2.531-4.031)   \<0.001        3.813 (2.680-5.423)   \<0.001   3.537 (2.707-4.622)   \<0.001   3.540 (2.709-4.625)

AJCC, American Joint Committee on Cancer; ENETS, European Neuroendocrine Tumor Society; HR, hazard ratio; mENETS, modified European Neuroendocrine Tumor Society; rENETS, reformed European Neuroendocrine Tumor Society.

###### 

Discriminatory capabilities of nomogram and independent prognostic factors.

  Variables                            OS      
  ------------------------------------ ------- -------------
  Nomogram (containing rENETS stage)   0.821   0.820-0.822
  Nomogram (containing mENETS stage)   0.821   0.820-0.822
  rENETS stage                         0.710   0.771-0.773
  mENETS stage                         0.710   0.771-0.773
  Grade                                0.689   0.688-0.670

rENETS, reformed European Neuroendocrine Tumor Society; mENETS, modified European Neuroendocrine Tumor Society; OS, overall survival.
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